Literature DB >> 8040907

Microorganisms and psoriasis.

E W Rosenberg1, P W Noah, R B Skinner.   

Abstract

It has been suggested previously that psoriasis is best explained as a distinctive inflammatory response to a variety of microbial stimuli, all acting primarily through activation of the alternative complement pathway. For the past several years we have conducted a "Problem Psoriasis Clinic" based on that premise. Patients are questioned, examined, and subjected to microbiologic laboratory investigations in an attempt to identify possibly relevant microorganisms, and then are treated with antibiotics. This article lists the most commonly found microorganisms in psoriasis patients and describes the usual treatment for each. Results obtained with this approach compare favorably with those achieved with more usual anti-psoriasis treatments. We recommend that a microbiologic investigation and a trial of antimicrobial treatment should precede any plan to treat psoriasis patients with anything more than the simplest topical agents.

Entities:  

Mesh:

Year:  1994        PMID: 8040907      PMCID: PMC2607638     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  28 in total

1.  [High phospholipase A-activity of Candida albicans isolated from the intestines of psoriatic patients].

Authors:  H Hänel; I Menzel; H Holzmann
Journal:  Mycoses       Date:  1988-09       Impact factor: 4.377

2.  Effect of topical applications of heavy suspensions of killed Malassezia ovalis on rabbit skin.

Authors:  E W Rosenberg; P Belew; G Bale
Journal:  Mycopathologia       Date:  1980-11-28       Impact factor: 2.574

3.  Patch tests with killed sonicated microflora in patients with psoriasis.

Authors:  C W Lober; P W Belew; E W Rosenberg; G Bale
Journal:  Arch Dermatol       Date:  1982-05

4.  Activation of the alternative pathway of complement by Malassezia ovalis (Pityrosporum ovale).

Authors:  P W Belew; E W Rosenberg; B R Jennings
Journal:  Mycopathologia       Date:  1980-03-31       Impact factor: 2.574

5.  Response of scalp psoriasis to oral ketoconazole.

Authors:  P M Farr; L B Krause; J M Marks; S Shuster
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

6.  Human keratinocytes and A-431 cells synthesize and secrete factor B, the major zymogen protease of the alternative complement pathway.

Authors:  K B Yancey; O Overholser; N Domloge-Hultsch; L J Li; S W Caughman; P Bisalbutra
Journal:  J Invest Dermatol       Date:  1992-03       Impact factor: 8.551

7.  Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin.

Authors:  R A Swerlick; M W Cunningham; N K Hall
Journal:  J Invest Dermatol       Date:  1986-09       Impact factor: 8.551

8.  Glucan-induced keratoderma in acquired immunodeficiency syndrome.

Authors:  M Duvic; M Reisman; V Finley; R Rapini; N R DiLuzio; P W Mansell
Journal:  Arch Dermatol       Date:  1987-06

9.  Treatment of pityriasis capitis (dandruff) with econazole nitrate.

Authors:  R Aron-Brunetière; D Dompmartin-Pernot; E Drouhet
Journal:  Acta Derm Venereol       Date:  1977       Impact factor: 4.437

10.  Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy.

Authors:  S Chaudhary; S A Bilinsky; J L Hennessy; S M Soler; S E Wallace; C M Schacht; A L Bisno
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

View more
  5 in total

Review 1.  Microbial ecology of the skin in the era of metagenomics and molecular microbiology.

Authors:  Geoffrey D Hannigan; Elizabeth A Grice
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

Review 2.  Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment.

Authors:  C J van der Vleuten; P C van de Kerkhof
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  MicroRNA-181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4.

Authors:  Cheng Feng; Ming Bai; Nan-Ze Yu; Xiao-Jun Wang; Zeng Liu
Journal:  J Cell Mol Med       Date:  2016-09-19       Impact factor: 5.310

4.  Relationship of Helicobacter pylori seroprevalence with the occurrence and severity of psoriasis.

Authors:  Priscila Miranda Diogo Mesquita; Augusto Diogo; Miguel Tanus Jorge; Alceu Luiz Camargo Villela Berbert; Sônia Antunes de Oliveira Mantese; José Joaquim Rodrigues
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

5.  Pathological role of interleukin-6 in psoriatic arthritis.

Authors:  Atsushi Ogata; Atsushi Kumanogoh; Toshio Tanaka
Journal:  Arthritis       Date:  2012-10-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.